PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells

He,Saifei; Ma,Xiaokun; Zheng,Ni; Wang,Guoyu; Wang,Menghan; Xia,Wei; Yu,Donghai

doi:10.3892/mmr.2020.11788

PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells

Authors:
- Saifei He
- Xiaokun Ma
- Ni Zheng
- Guoyu Wang
- Menghan Wang
- Wei Xia
- Donghai Yu
View Affiliations

Affiliations: Department of Science and Research, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China, Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China, Department of Science and Education, The Municipal Health Commission, Shanghai 200125, P.R. China
Published online on: December 17, 2020 https://doi.org/10.3892/mmr.2020.11788
Article Number: 149
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have reported that aberrant PR domain zinc finger protein 14 (PRDM14) expression is associated with the therapeutic sensitivity of cancer cells to drugs. However, its role in lung adenocarcinoma (LUAD) remains unclear. The present study aimed to determine the functions of knockdown or overexpression of PRDM14 in the chemosensitivity and glycolysis of LUAD cells. PRDM14 expression was analyzed in lung cancer tissues from patients resistant and sensitive to cisplatin (DDP), as well as in LUAD cell lines A549 and DDP‑resistant A549 (A549/DDP) using reverse transcription quantitative‑PCR and western blotting. Additionally, apoptosis was analyzed by flow cytometry, and flow cytometry and biochemical analysis was used to analyze glycolysis, indicated by glucose uptake and lactate release. The results of the present study demonstrated that PRDM14 expression was upregulated in patients with DDP‑resistant LUAD and DDP‑resistant cell lines. Overexpression of PRDM14 suppressed the sensitivity of A549 cells to DDP and silencing of PRDM14 using shRNA targeting PRDM14 promoted the sensitivity of A549/DDP cells to DDP, compared with that in the respective control groups. In mice with xenograft tumors, knockdown of PRDM14 using shRNA targeting PRDM14 inhibited the A549/DDP cell‑derived tumor growth compared with scramble shRNA. The results of the glycolysis assays demonstrated that PRDM14 silencing inhibited glucose uptake, lactate release and glucose transporter 1 expression in A549/DDP cells compared with those in the control cells. PRDM14 overexpression relieved the inhibitory effects of 3‑bromopyruvate, a potent glycolytic inhibitor for glycolysis, on glucose uptake and lactate release in A549 cells compared with those in the control cells. Therefore, the results of the present study suggested that PRDM14 may inhibit the chemosensitivity and promote glycolysis in human LUAD cells.

View Figures

View References

1	Pan X, Chen Y, Shen Y and Tantai J: Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7. Cell Death Dis. 10:4292019. View Article : Google Scholar : PubMed/NCBI
2	Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, et al: Immune cell composition in human non-small cell lung cancer. Front Immunol. 9:31012018. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
4	Rossi A and Di Maio M: Platinum-based chemotherapy in advanced non-small-cell lung cancer: Optimal number of treatment cycles. Expert Rev Anticancer Ther. 16:653–660. 2016. View Article : Google Scholar : PubMed/NCBI
5	Li FL, Liu JP, Bao RX, Yan GQ, Feng X, Xu YP, Sun YP, Yan W, Ling ZQ, Xiong Y, et al: Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat Commun. 9:5082018. View Article : Google Scholar : PubMed/NCBI
6	Bose S and Le A: Glucose metabolism in cancer. Adv Exp Med Biol. 1063:3–12. 2018. View Article : Google Scholar : PubMed/NCBI
7	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kim JH, Nam B, Choi YJ, Kim SY, Lee JE, Sung KJ, Kim WS, Choi CM, Chang EJ, Koh JS, et al: Enhanced glycolysis supports cell survival in EGFR-Mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation. Cancer Res. 78:4482–4496. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zhang W, Bouchard G, Yu A, Shafiq M, Jamali M, Shrager JB, Ayers K, Bakr S, Gentles AJ, Diehn M, et al: GFPT2-expressing cancer-associated fibroblasts mediate metabolic reprogramming in human lung adenocarcinoma. Cancer Res. 78:3445–3457. 2018.PubMed/NCBI
10	Higashi K, Yamagishi T, Ueda Y, Ishigaki Y, Shimasaki M, Nakamura Y, Oguchi M, Takegami T, Sagawa M and Tonami H: Correlation of HIF-1α/HIF-2α expression with FDG uptake in lung adenocarcinoma. Ann Nucl Med. 30:708–715. 2016. View Article : Google Scholar : PubMed/NCBI
11	Huber SM, Misovic M, Mayer C, Rodemann HP and Dittmann K: EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiother Oncol. 103:373–379. 2012. View Article : Google Scholar : PubMed/NCBI
12	Ciribilli Y, Singh P, Inga A and Borlak J: c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma. Oncotarget. 7:65514–65539. 2016. View Article : Google Scholar : PubMed/NCBI
13	Gong T, Cui L, Wang H, Wang H and Han N: Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J Transl Med. 16:1642018. View Article : Google Scholar : PubMed/NCBI
14	Liu J, Lu F, Gong Y, Zhao C, Pan Q, Ballantyne S, Zhao X, Tian S and Chen H: High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma. Hum Pathol. 77:54–62. 2018. View Article : Google Scholar : PubMed/NCBI
15	Zhang L, Zhang Z and Yu Z: Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma. J Transl Med. 17:4232019. View Article : Google Scholar : PubMed/NCBI
16	Tan SX, Hu RC, Xia Q, Tan YL, Liu JJ, Gan GX and Wang LL: The methylation profiles of PRDM promoters in non-small cell lung cancer. Onco Targets Ther. 11:2991–3002. 2018. View Article : Google Scholar : PubMed/NCBI
17	Fog CK, Galli GG and Lund AH: PRDM proteins: Important players in differentiation and disease. Bioessays. 34:50–60. 2012. View Article : Google Scholar : PubMed/NCBI
18	Hohenauer T and Moore AW: The prdm family: Expanding roles in stem cells and development. Development. 139:2267–2282. 2012. View Article : Google Scholar : PubMed/NCBI
19	Taniguchi H and Imai K: PRDM14, a zinc finger protein, regulates cancer stemness. Methods Mol Biol. 1867:3–13. 2018. View Article : Google Scholar : PubMed/NCBI
20	Bi HX, Shi HB, Zhang T and Cui G: PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro. Chin Med J (Engl). 128:373–377. 2015. View Article : Google Scholar : PubMed/NCBI
21	Taniguchi H and Imai K: Silencing PRDM14 via oligonucleotide therapeutics suppresses tumorigenicity and metastasis of breast cancer. Methods Mol Biol. 1974:233–243. 2019. View Article : Google Scholar : PubMed/NCBI
22	Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, Newsom-Davis T, von Karstedt S, Graves J and Walczak H: TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene. 34:2138–2144. 2015. View Article : Google Scholar : PubMed/NCBI
23	Xiong S, Zheng Y, Jiang P, Liu R, Liu X and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 7:805–814. 2011. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Sakurai Y, Ichinoe M, Yoshida K, Nakazato Y, Saito S, Satoh M, Nakada N, Sanoyama I, Umezawa A, Numata Y, et al: Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors. Cancer Lett. 489:100–110. 2020. View Article : Google Scholar : PubMed/NCBI
26	Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T and Kitanaka C: Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells. Oncotarget. 9:32667–32679. 2018. View Article : Google Scholar : PubMed/NCBI
27	Fan T, Sun G, Sun X, Zhao L, Zhong R and Peng Y: Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis: Implications in tumor treatment. Cancers (Basel). 11:3172019. View Article : Google Scholar
28	Zhang Q, Pan J, North PE, Yang S, Lubet RA, Wang Y and You M: Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev Res (Phila). 5:717–725. 2012. View Article : Google Scholar : PubMed/NCBI
29	Igarashi H, Taniguchi H, Nosho K, Ishigami K, Koide H, Mitsuhashi K, Okita K, Takemasa I, Imai K and Nakase H: PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer. Clin Transl Oncol. 22:1126–1137. 2020. View Article : Google Scholar : PubMed/NCBI
30	Moriya C, Taniguchi H, Miyata K, Nishiyama N, Kataoka K and Imai K: Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice. Carcinogenesis. 38:638–648. 2017. View Article : Google Scholar : PubMed/NCBI
31	Liang T, Ye X, Yan D, Deng C, Li Z and Tian B: FAM46B promotes apoptosis and inhibits glycolysis of prostate cancer through inhibition of the MYC-LDHA axis. Onco Targets Ther. 13:8771–8782. 2020. View Article : Google Scholar : PubMed/NCBI
32	Heydarzadeh S, Moshtaghie AA, Daneshpoor M and Hedayati M: Regulators of glucose uptake in thyroid cancer cell lines. Cell Commun Signal. 18:832020. View Article : Google Scholar : PubMed/NCBI
33	Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, et al: MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 8:146342017. View Article : Google Scholar : PubMed/NCBI
34	Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI
35	Kikuchi R, Iwai Y, Tsuji T, Watanabe Y, Koyama N, Yamaguchi K, Nakamura H and Aoshiba K: Hypercapnic tumor microenvironment confers chemoresistance to lung cancer cells by reprogramming mitochondrial metabolism in vitro. Free Radic Biol Med. 134:200–214. 2019. View Article : Google Scholar : PubMed/NCBI
36	Lu Y, Wan Z, Zhang X, Zhong X, Rui L and Li Z: PRDM14 inhibits 293T cell proliferation by influencing the G1/S phase transition. Gene. 595:180–186. 2016. View Article : Google Scholar : PubMed/NCBI
37	Snellenberg S, Cillessen SA, Van Criekinge W, Bosch L, Meijer CJLM, Snijders PJF and Steenbergen RDM: Methylation-mediated repression of PRDM14 contributes to apoptosis evasion in HPV-positive cancers. Carcinogenesis. 35:2611–2618. 2014. View Article : Google Scholar : PubMed/NCBI
38	Moriya C, Taniguchi H, Nagatoishi S, Igarashi H, Tsumoto K and Imai K: PRDM14 directly interacts with heat shock proteins HSP90α and glucose-regulated protein 78. Cancer Sci. 109:373–383. 2018. View Article : Google Scholar : PubMed/NCBI
39	Feng Y, Hu J, Xie D, Qin J, Zhong Y, Li X, Xiao W, Wu J, Tao D, Zhang M, et al: Subcellular localization of caspase-3 activation correlates with changes in apoptotic morphology in MOLT-4 leukemia cells exposed to X-ray irradiation. Int J Oncol. 27:699–704. 2005.PubMed/NCBI